Propanc Biopharma’s PRP to Target 80 – 90% of Cancer Cases
PRP Prevents Recurrence and Metastasis by Targeting and Eradicating Cancer Stem Cells MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s lead product candidate, PRP, targets solid tumors, which accounts for 80 – … [Read more…]
